Mounjaro Wins FDA Approval to Reduce Cardiovascular Risk in Type 2 Diabetes
The FDA approved Mounjaro (tirzepatide) on August 28 to reduce the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes who are at high risk. The approval was based on the SURPASS-CVOT trial, which enrolled more than 13,000 participants across 30 countries. Mounjaro is the first dual GIP and GLP-1 receptor agonist to receive this indication.
The FDA approved Mounjaro (tirzepatide) on August 28, 2026, for a new indication: reducing the risk of major adverse cardiovascular events, including cardiovascular death, non-fatal heart attack, and non-fatal stroke, in adults with type 2 diabetes who are at high risk.
Eli Lilly's Mounjaro is a dual GIP and GLP-1 hormone receptor agonist. It is the first medication of its class to receive FDA approval for lowering cardiovascular risk in this patient population.
The approval was based on data from the SURPASS-CVOT trial, the largest and longest study conducted for tirzepatide. The Phase 3 trial enrolled more than 13,000 participants across 30 countries, with a median follow-up of approximately four years.
The trial compared Mounjaro head-to-head against Trulicity (dulaglutide), a GLP-1 receptor agonist already known for cardiovascular protection. Mounjaro demonstrated non-inferiority to Trulicity, with an 8 percent lower rate of cardiovascular death, heart attack, or stroke.
Medical experts note that cardiovascular disease is the leading cause of death for people with type 2 diabetes, yet it is frequently overlooked in favor of glucose management alone. The new indication gives clinicians another tool to address both conditions simultaneously.
The safety profile of Mounjaro remained consistent with its established clinical data. The most common adverse events were gastrointestinal and typically occurred during the initial dose-escalation phase. Existing warnings regarding pancreatitis, thyroid C-cell tumors, and gallbladder disease remain in effect.
